Instem plc H2 China Market Update

TIDMINS

Instem plc

21 December 2021

Instem plc

("Instem" or the "Company")

H2 China Market Update

Strong SaaS growth with new and existing clients

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces further progress in the Chinese market in the second half of this financial year. Contract successes include Provantis(R) preclinical software solution suite orders for a significant number of additional licensed users from two long-standing customers, reinforcing Instem's strong existing relationships, and four additional new clients. All of these orders are Software-as-a-Service ("SaaS") subscriptions.

Instem will provide the new customers with solutions incorporating a range of modules across areas including general toxicology, clinical pathology, pathology and implementation services. The deals highlight the strength of the Company's position in the Chinese market, with the SaaS platform providing increasing earnings visibility and underlying margins growth.

Phil Reason, CEO of Instem plc, said: " We are very pleased to achieve these contracts, demonstrating the strength of our long-standing client relationships, the continuing transition to SaaS, as well as momentum in securing new business. The two existing customers have been clients for over seven years, illustrating the long-term nature of our relationships and how Instem supports its clients' growth.

"As reflected in our interim statement, Instem continues to capitalise on its market-leading position in China with these orders, highlighting the health of the early-phase R&D pipeline in this substantial market."

For further information, please contact:

 
 Instem plc                           Via Walbrook 
 Phil Reason, CEO 
 Nigel Goldsmith, CFO 
 
 Singer Capital Markets (Nominated 
  Adviser & Broker)                   +44 (0) 20 7496 3000 
 Peter Steel 
  Alex Bond 
  Rachel Hayes 
 
 Walbrook Financial PR                +44 (0) 20 7933 8780 
 Tom Cooper                           instem@walbrookpr.com 
 Nick Rome 
 Nicholas Johnson

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

   To learn more about Instem solutions and its mission, please visit   www.instem.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRADKKBQCBDDFBB

(END) Dow Jones Newswires

December 21, 2021 02:00 ET (07:00 GMT)

Instem (LSE:INS)
Historical Stock Chart
From May 2024 to Jun 2024